FDA Approved: ALHEMO — Supplemental Application (Novo Nordisk)

View source ↗

Summary

The FDA document relates to a supplemental application for ALHEMO (concizumab) submitted by Novo Nordisk.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• ALHEMO (Concizumab)

Snippet

SUPPL AP for ALHEMO (CONCIZUMAB)